FDA-approved generic pergolide reaches equine PPID market

CURRENT BRIEF VERSION: Dechra’s Zygolide, a 1 mg pergolide tablet for horses with pituitary pars intermedia dysfunction, or PPID, has entered the U.S. market as the first FDA-approved generic alternative to Prascend. FDA approved the product on December 19, 2025, and announced the decision publicly on January 9, 2026. Zygolide is prescription-only, bioequivalent to Prascend, and marketed with features Dechra says are meant to support day-to-day administration, including peppermint flavoring and 360-degree scoring for dose splitting. In promotional placements in The Horse, Dechra has also leaned into owner-facing messaging around helping horses “feel their best” and “rediscover the partnership,” underscoring the company’s broader compliance and quality-of-life pitch. The company has also positioned it as a lower-cost option for long-term PPID management. (fda.gov)

Why it matters: For equine veterinarians, the approval adds a new FDA-approved pergolide option in a category where adherence, dose adjustments, and long-term affordability can shape outcomes in older horses. The label keeps the familiar starting dose of 2 mcg/kg once daily, with adjustment to effect up to 4 mcg/kg daily, and FDA’s approval pathway means the generic met bioequivalence standards rather than requiring a new standalone efficacy package. Dechra’s early advertising also makes clear that the launch is being framed not just around price, but around preserving horse-owner quality of life and the day-to-day bond that can be strained by chronic disease management. That could give clinicians and pet parents another way to manage PPID while staying within an approved product framework. (animaldrugsatfda.fda.gov)

What to watch: Watch for how quickly veterinarians, pharmacies, and pet parents adopt Zygolide, especially if pricing and palatability meaningfully improve long-term compliance in senior horses with PPID. It will also be worth watching whether Dechra’s quality-of-life messaging in The Horse resonates with owners making long-horizon treatment decisions. (dechra-us.com)